English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
Lepu Biopharma: Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication, Breakthrough therapy designation granted by the CDE to MRG003 for the treatment of R/M NPC
Sep 29, 2022 15:40 HKT
臻和科技拟赴港上市:中国肿瘤分子诊断及检测的领导者 技术及财务共筑企业核心竞争力
Sep 29, 2022 14:35 HKT
臻和科技擬赴港上市:中國腫瘤分子診斷及檢測的領導者 技術及財務共築企業核心競爭力
Sep 29, 2022 14:34 HKT
Taiwan Stays at the Forefront of Medical Technology
Sep 29, 2022 13:00 HKT
Claudin18.2, a shining star in gastric cancer, Transcenta's TST001 stands at the global forefront
Sep 28, 2022 19:24 HKT
Avance Clinical Wins International Health Award for Biotech CRO Services
Sep 28, 2022 16:00 HKT
艾美疫苗宣布于港交所主板上市计划
Sep 23, 2022 17:19 HKT
艾美疫苗宣佈於港交所主板上市計劃
Sep 23, 2022 17:15 HKT
AIM Vaccine Announces Proposed Listing on the Main Board of SEHK
Sep 23, 2022 17:06 HKT
Malaysian Genomics Grows Presence in Thailand
Sep 23, 2022 14:00 HKT
深睿医疗联合华西医院最新研究被 NPJ-Digital Medicine收录,全面提高肺部疾病诊断效率和准确性
Sep 22, 2022 18:00 HKT
深睿醫療聯合華西醫院最新研究被 NPJ-Digital Medicine收錄,全面提高肺部疾病診斷效率和準確性
Sep 22, 2022 18:00 HKT
Agilis Robotics Targeting its Pre-B Round Fund-raising to be Completed by 2022
Sep 22, 2022 14:13 HKT
Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah
Sep 21, 2022 19:00 HKT
Sirnaomics将在第二届年度寡核苷酸疗法与递送会议上演讲适用于癌症的siRNA疗法和GalAhead(TM)平台项目的最新进展
Sep 20, 2022 23:52 HKT
Sirnaomics將在第二屆年度寡核苷酸療法與遞送會議上演講適用於癌症的siRNA療法和GalAhead(TM)平台項目的最新進展
Sep 20, 2022 23:51 HKT
Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference
Sep 20, 2022 23:50 HKT
노보텍,제6회CGTWA 컨퍼런스에서‘2022세포유전자치료제우수상’수상
Sep 17, 2022 07:00 HKT
Novotech 在第六届细胞与基因治疗世界亚洲会议上荣获 2022 年细胞与基因卓越奖
Sep 16, 2022 10:00 HKT
Novotech 在第六屆細胞與基因治療世界亞洲會議上榮獲 2022 年細胞與基因卓越獎
Sep 16, 2022 10:00 HKT
<< Previous  Next >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: